Immunoglobulin E-mediated severe anaphylaxis to paclitaxel.
Prieto García
A
A
Allergy Service, Hospital General Universitario Gregorio Marañón, Madrid, Spain. aprieto.hgugm@salud.madrid.org
Pineda de la Losa
F
F
D000707:Anaphylaxis; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D001249:Asthma / Q000150:complications; D002945:Cisplatin / Q000008:administration & dosage / Q000009:adverse effects; D003841:Deoxycytidine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives; D004342:Drug Hypersensitivity / Q000175:diagnosis* / Q000276:immunology / Q000503:physiopathology; D004417:Dyspnea; D000939:Epitopes / Q000378:metabolism; D005260:Female; D006801:Humans; D006969:Hypersensitivity, Immediate / Q000139:chemically induced / Q000175:diagnosis* / Q000276:immunology / Q000503:physiopathology; D007022:Hypotension; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology; D008875:Middle Aged; D009369:Neoplasms / Q000150:complications / Q000188:drug therapy*; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects*; D001261:Pulmonary Atelectasis; D012074:Remission Induction; D012882:Skin Tests; D000093542:Gemcitabine
D000939:Epitopes; D003841:Deoxycytidine; D007073:Immunoglobulin E; D017239:Paclitaxel; D002945:Cisplatin; D000093542:Gemcitabine